Ortin Global Quarterly Results for Trading Insights
In Mar 2012, Ortin Global (ORTINGLOBE) reported revenue ₹18 Cr and net profit ₹-2 Cr. Also explore ORTINGLOBE share price history to track price trends across different timeframes.
ORTINGLOBE Quarterly Results — Revenue, Profit & EPS Highlights
Ortin Global latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit ORTINGLOBE share price screener.
- Revenue of ₹18 Cr in Mar 2012 (+38.5% vs Jun 2012)
- Net Profit of ₹-2 Cr in Mar 2012
- EBITDA of ₹-3 Cr in Mar 2012 (-200.0% vs Jun 2012)
- Operating Margin of -19.0% in Mar 2012 (-14.0pp vs Jun 2012)
- Earnings Per Share of ₹-1.13 in Mar 2012 (-534.6% vs Jun 2012)
Ortin Global Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ORTINGLOBE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2012 | Jun 2012 | QoQ | YoY |
|---|---|---|---|---|
| Revenue (₹ Cr) | 18 | 13 | 38.5% | - |
| Net Profit (₹ Cr) | -2 | 0 | - | - |
| EBITDA (₹ Cr) | -3 | -1 | - | - |
| EPS (₹) | -1.13 | 0.26 | - | - |
| Operating Margin (%) | -19.0% | -5.0% | - | - |
ORTINGLOBE Share Price Trend — 1-Year Movement Across Quarterly Results
Ortin Global 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse ORTINGLOBE annual financials for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ORTINGLOBE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Ortin Global latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1875.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 165.9 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8588.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4971.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.9 |
|
Cipla
Mar 2026 |
₹117,137.57 Cr | 1431.1 | 6,612 | 543 | -9.3% | - | 8.2% | 208.3 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1115.6 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.2 |
All amounts in ₹ Crores